Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 5/20 | 0.45 |
| ▸ | ESR2 | Q92731 | 5/20 | 0.45 |
| ▸ | AR | P10275 | 4/20 | 0.45 |
| ▸ | SHBG | P04278 | 3/20 | 0.45 |
| ▸ | SERPINA6 | P08185 | 2/20 | 0.45 |
| ▸ | G6PD | P11413 | 2/20 | 0.44 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.43 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.43 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | GUSB | P08236 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4152712 | 1.00 | ESR1 (0.45) | ESR1ESR2ARSHBGSERPINA6 | |
| SCHEMBL3112594 | 1.00 | ESR1 (0.45) | ESR1ESR2ARSHBGSERPINA6 | |
| SCHEMBL6899626 | 0.89 | SHBG (0.44) | ESR1ESR2ARSHBGSERPINA6 | |
| SCHEMBL9853326 | 0.84 | SHBG (0.41) | ESR1ESR2ARSHBGSERPINA6 | |
| SCHEMBL7259576 | 0.84 | SHBG (0.41) | ESR1ESR2ARSHBGSERPINA6 | |
| SCHEMBL8707384 | 0.82 | TDP1 (0.49) | ARCYP17A1SRD5A2MEN1CYP3A4 | |
| SCHEMBL9939636 | 0.82 | CYP19A1 (0.46) | ESR1ESR2ARSHBGSERPINA6 | |
| SCHEMBL15904745 | 0.81 | ABCC4 (0.50) | TSHR | |
| SCHEMBL9163829 | 0.81 | ESR2 (0.69) | ESR1ESR2ARSHBGSERPINA6 | |
| SCHEMBL9163839 | 0.81 | ESR2 (0.69) | ESR1ESR2ARSHBGSERPINA6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100022494-A1 | Method, device, and kit for maintaining physiological levels of steroid hormone in a subject | SEARETE LLC, A LIMITED LIABILITY CORPORATION OF THE STATE OF DELAWARE | 2010-01-28 | — | — | US | disclosed |
| US-20090137541-A1 | Novel Series of Imidazolyl Substituted Steroidal and Indan-1-One Derivatives | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2009-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137541-A1 | Novel Series of Imidazolyl Substituted Steroidal and Indan-1-One Derivatives | NR5A1, NR3C2, CYP17A1 | ESR1 188/4885ESR2 101/4885AR 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.